Cardiac myosin activation: A potential therapeutic approach for systolic heart failure

Science

Volumn 331, Issue 6023, 2011, Pages 1439-1443

  Malik, Fady I ^a   Hartman, James J ^a   Elias, Kathleen A ^a   Morgan, Bradley P ^a   Rodriguez, Hector ^a   Brejc, Katjuša ^a   Anderson, Robert L ^a   Sueoka, Sandra H ^a   Lee, Kenneth H ^a   Finer, Jeffrey T ^a   Sakowicz, Roman ^a   Baliga, Ramesh ^a   Cox, David R ^a   Garard, Marc ^a   Godinez, Guillermo ^a   Kawas, Raja ^a   Kraynack, Erica ^a   Lenzi, David ^a   Lu, Pu Ping ^a   Muci, Alexander ^a   Niu, Congrong ^a   Qian, Xiangping ^a   Pierce, Daniel W ^a   Pokrovskii, Maria ^a   Suehiro, Ion ^a   Sylvester, Sheila ^a   Tochimoto, Todd ^a   Valdez, Corey ^a   Wang, Wenyue ^a   Katori, Tatsuo ^b   Kass, David A ^b   Shen, You Tang ^c,e   Vatner, Stephen F ^c,d   Morgans, David J ^a   more..

^a Cytokinetics Inc   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c CV Dynamics Inc   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATE; CALCIUM; CARDIAC MYOSIN; DOBUTAMINE; ISOPRENALINE; OMECAMTIV MECARBIL;

CARDIOLOGY; CARDIOVASCULAR DISEASE; CATALYSIS; DISEASE TREATMENT; DRUG; PHOSPHATE (ORGANIC); PROTEIN;

ACTIN MYOSIN INTERACTION; ALLOSTERISM; ARTICLE; CALCIUM TRANSPORT; DRUG BINDING SITE; DRUG PROTEIN BINDING; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; SYSTOLIC HEART FAILURE; TURNOVER TIME;

ACTINS; ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ADRENERGIC BETA-AGONISTS; ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CALCIUM; CARDIAC MYOSINS; CARDIAC OUTPUT; DOGS; FEMALE; HEART FAILURE, SYSTOLIC; ISOPROTERENOL; MALE; MICROFILAMENTS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHATES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; UREA; VENTRICULAR FUNCTION, LEFT;

ANIMALIA;

EID: 79952781139     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1200113     Document Type: Article

References (28)

1. D. Lloyd-Jones et al., Circulation 121, 948 (2010).
2. L. R. Loehr, W. D. Rosamond, P. P. Chang, A. R. Folsom, L. E. Chambless, Am. J. Cardiol. 101, 1016 (2008).
3. K. F. Adams Jr. et al., Am. Heart J. 149, 209 (2005).
4. J. J. V. McMurray, N. Engl. J. Med. 362, 228 (2010).
5. D. A. Kass, R. J. Solaro, Circulation 113, 305 (2006).
6. T. Pollard, W. Earnshaw, Cell Biology (Saunders/Elsevier, Philadelphia, ed. 2, 2008) pp. 705-725.
7. B. P. Morgan et al., ACS Med Chem Lett. 1, 472 (2010).
8. Y. T. Shen et al., Circ Heart Fail. 3, 522 (2010).
9. Materials and methods are available as supporting material on Science Online.
10. R. W. Lymn, E. W. Taylor, Biochemistry 10, 4617 (1971).
11. H. L. Sweeney, A. Houdusse, Annu. Rev. Biophys. 39, 539 (2010).
12. K. C. Holmes, I. Angert, F. J. Kull, W. Jahn, R. R. Schröder, Nature 425, 423 (2003).
13. M. Brune, J. L. Hunter, J. E. Corrie, M. R. Webb, Biochemistry 33, 8262 (1994).
14. E. M. De La Cruz, E. M. Ostap, Methods Enzymol. 455, 157 (2009).
15. T. Suzuki et al., Circ. Heart Fail. 2, 334 (2009).
16. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
17. I. Rayment et al., Science 261, 50 (1993).
18. L. Cleemann, M. Morad, J. Physiol. 432, 283 (1991).
19. In the online materials, a side-by-side movie shows several heartbeats of a short-axis echocardiogram in an anesthetized beagle before (on the left) and after (on the right) a 1-hour infusion of omecamtiv mecarbil at 1 mg/kg of body weight per hour. In this view, the left ventricular cavity is in the middle of a ring of contracting myocardium.
20. K. Komamura et al., J. Clin. Invest. 89, 1825 (1992).
21. Y. T. Shen, J. J. Lynch, R. P. Shannon, R. T. Wiedmann, Am. J. Physiol. 277, H388 (1999).
22. P. N. Banfor et al., Am. J. Physiol. Heart Circ. Physiol. 294, H238 (2008).
23. H. Suga, K. Sagawa, Circ. Res. 35, 117 (1974).
24. J. Grimsby et al., Science 301, 370 (2003).
25. J. P. Stasch et al., Br. J. Pharmacol. 136, 773 (2002).
26. J. A. Zorn, J. A. Wells, Nat. Chem. Biol. 6, 179 (2010).
27. J. W. Petersen, G. M. Felker, Crit. Care Med. 36 (suppl.), S106 (2008).
28. We thank J. Chabala, C. Homcy, T. A. Pollard, J. H. Sabry, R. J. Solaro, J. A. Spudich, J. R. Teerlink, and R. D. Vale for their advice over the course of this work; A. Franklin and S. Hollenbach for their contributions to the conduct of some of these studies; and M. Rowley and J. Goldstein for assistance in preparing the manuscript. Y.-T.S., D.A.K., and S.F.V. are members of the Scientific Advisory Board and received research support, compensation, and stock options (D.A.K. and S.F.V.) from Cytokinetics. Cytokinetics holds a patent on omecamtiv mecarbil (U.S. Patent no. 7,507,735); Amgen is a licensee of this patent. Support provided by Small Business Innovation Research grant, NIH (1-R43-HL-66647-1) and Cytokinetics, Inc.